Abnormal Mechanisms of Plasticity and Metaplasticity in Autism Spectrum Disorders and Fragile X Syndrome [0.03%]
自闭症谱系障碍和脆性X综合征中的可塑性和元可塑性的异常机制
Lindsay M Oberman,Fritz Ifert-Miller,Umer Najib et al.
Lindsay M Oberman et al.
Objectives: Multiple lines of evidence from genetic linkage studies to animal models implicate aberrant cortical plasticity and metaplasticity in the pathophysiology of autism spectrum disorder (ASD) and fragile X syndrom...
From the Editor-in-Chief's Desk [0.03%]
主编来信
Harold S Koplewicz
Harold S Koplewicz
Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting [0.03%]
一种缓释型口腔崩解甲基苯丙胺片剂治疗6-12岁注意力缺陷多动障碍患儿的疗效、安全性和耐受性：实验室教室设置下的研究
Ann C Childress,Scott H Kollins,Andrew J Cutler et al.
Ann C Childress et al.
Objective: Methylphenidate extended-release orally disintegrating tablets (MPH XR-ODTs) represent a new technology for MPH delivery. ODTs disintegrate in the mouth without water and provide a pharmacokinetic profile that ...
Randomized Controlled Trial
Journal of child and adolescent psychopharmacology. 2017 Feb;27(1):66-74. DOI:10.1089/cap.2016.0002 2017
Do Antidepressants Induce Psychosis in Children and Adolescents? A Naturalistic Study in Ambulatory Pediatric Population [0.03%]
抗抑郁药会诱发儿童及青少年的精神病吗？一项门诊儿科人群的自然研究
Mariela Mosheva,Ehud Mekori,Shir Kantor et al.
Mariela Mosheva et al.
Objective: The aim of the present study was to examine if selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) induce psychotic symptoms in children and adolescent outpa...
Neural Correlates of Antidepressant Treatment Response in Adolescents with Major Depressive Disorder [0.03%]
青少年抑郁症患者抗抑郁治疗反应的神经相关性研究
Kathryn R Cullen,Bonnie Klimes-Dougan,Dung Pham Vu et al.
Kathryn R Cullen et al.
Objective: The neural changes underlying response to antidepressant treatment in adolescents are unknown. Identification of neural change correlates of treatment response could (1) aid in understanding mechanisms of depre...
Dhrubajyoti Bhuyan,Soumitra Ghosh,Arnab Bhattacharya et al.
Dhrubajyoti Bhuyan et al.
Asenapine is a sublingually absorbed newer second-generation antipsychotic that is approved for the treatment of schizophrenia and bipolar disorder in patients, with a lower extrapyramidal adverse effect potential. We report an adolescent b...
The Prevalence of Stimulant and Antidepressant Use by Australian Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Major Depressive Disorder: A National Survey [0.03%]
澳大利亚儿童及青少年注意缺陷多动障碍和重性抑郁障碍的发病率：一项全国调查
Michael G Sawyer,Christy E Reece,Alyssa C P Sawyer et al.
Michael G Sawyer et al.
Objectives: To identify the prevalence of stimulant and antidepressant medication use by children and adolescents with symptoms meeting the criteria for attention-deficit/hyperactivity disorder (ADHD) and major depressive...
Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review [0.03%]
儿童及青少年精神分裂症样精神病的临床特征及其预后的预测因素：系统性综述
Marie Stentebjerg-Olesen,Anne K Pagsberg,Anders Fink-Jensen et al.
Marie Stentebjerg-Olesen et al.
Objective: Treatment of early-onset schizophrenia spectrum psychosis (EOS) is hampered by limited data on clinical presentation and illness course. We aimed to systematically review the clinical characteristics, diagnosti...
Childhood Attention-Deficit/Hyperactivity Disorder Prescribing by Prescriber Type and Specialty in Oregon Medicaid [0.03%]
俄勒冈州医疗补助计划中儿科注意力缺陷/多动障碍处方的开具者类型和专业分类
Tracy A Klein,Shannon Panther,Teri Woo et al.
Tracy A Klein et al.
Objective: This study compares nurse practitioner (NP) and physician (MD/DO) prescribing patterns for treatment of children with an attention-deficit/hyperactivity disorder (ADHD)-related diagnosis covered by Oregon Medic...